DATA GRAPHICS | Data Byte
Mounjaro overtakes Keytruda for the first time
Lilly’s diabetes brand alone outsold Keytruda in 1Q26, while combined tirzepatide sales topped the cancer drug by nearly $5B in FY25
May 7, 2026 10:20 PM UTC
Eli Lilly’s tirzepatide has not only overtaken Merck’s Keytruda as the world’s top-selling drug, but Mounjaro, the diabetes brand of tirzepatide, has now outsold the cancer immunotherapy on its own for the first time.
Eli Lilly and Co. (NYSE:LLY) reported Mounjaro sales of $8.7 billion in 1Q25, while Merck & Co. Inc. (NYSE:MRK) reported $8 billion in sales of Keytruda, including new subcutaneous formulation Keytruda Qlex...